Literature DB >> 30985394

The Opioid Wars-CON: The Risks of Opioids for Pain Management Outweigh the Benefits.

Thomas A Anderson1.   

Abstract

The entire field of medicine, not just anesthesiology, has grown comfortable with the risks posed by opioids; but these risks are unacceptably high. It is time for a dramatic paradigm shift. If used at all for acute or chronic pain management, they should be used only after consideration and maximizing the use of nonopioid pharmacologic agents, regional analgesia techniques, and nonpharmacologic methods. Opioids poorly control pain, their intraoperative use may increase the risk of recurrence of some types of cancer, and they have a large number of both minor and serious side effects. Furthermore, there are a myriad of alternative analgesic strategies that provide superior analgesia, decrease recovery time, and have fewer side effects and risks associated with their use. In this article the negative consequences of opioid use for pain, appropriate alternatives to opioids for analgesia, and the available evidence in pediatric populations for both are described.

Entities:  

Year:  2019        PMID: 30985394     DOI: 10.1097/AJP.0000000000000702

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  2 in total

1.  Lessons from the Analysis of a Retrospective Cohort of Patients Who Underwent Large Open Abdominal Surgery Under Total Intravenous Opioid-Free Anesthesia.

Authors:  Jean-Pierre Estebe; Mathieu Morel; Timothée Daouphars; Elric Ardant; Chloé Rousseau; Anaïs Drouet; Camille Bosquet; Karim Boudjema
Journal:  Drugs Real World Outcomes       Date:  2020-11-24

2.  Pain Management for Dental Medicine in 2021: Opioids, Coronavirus and Beyond.

Authors:  Steven J Scrivani; David A Keith; Ronald J Kulich; Alexandre F DaSilva; R Bruce Donoff; Shruti Handa; Nicole Holland; Mark A Lerman; Jenna L McCauley; Lori Reisner; Cory M Resnick; Christian S Stohler; Alexis Vasciannie; Matthew Fortino; Michael E Schatman
Journal:  J Pain Res       Date:  2021-05-24       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.